An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.
NCT ID: NCT02250482
Last Updated: 2018-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2001-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.
NCT02246868
A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.
NCT02246894
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
NCT02246881
Optivate in People With Von Willebrand Disease Undergoing Surgery
NCT00404300
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.
NCT02250560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Optivate®
Optivate® (Human Coagulation Factor VIII)
Optivate® (Human Coagulation Factor VIII)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optivate® (Human Coagulation Factor VIII)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bio Products Laboratory
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinika Haematologii, Akademia Medyczna w Gdansku, ul.
Debinki 7, 80-211 Gdansk, , Poland
Klinika Haematologii, Akademia Medyczna w Lublinie, ul.
Dr K Jaczewskiego 8, 20-090, Lublin, , Poland
Klinika Haematologii, Akademia Medyczna w Poznaniu, ul.
Szkolna 8/12, 61-833 Poznan, , Poland
Haemophilia Centre, Addenbrooke's Hospital, Hills Road
Cambridge, , United Kingdom
Haemophilia Centre, University Dept. of Haemophilia, Manchester Royal Infirmary
Manchester, , United Kingdom
Haemophilia Centre, University Hospital, Queens Medical Centre, Clifton Boulevard
Nottingham, , United Kingdom
Sheffield Haemophilia & Thrombosis Centre, Royal Hallamshire Hospital, Glossop Road
Sheffield, , United Kingdom
Haemophilia Centre, Southampton General Hospital, Tremona Road
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8VWF02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.